Imugene Ltd (IMU)

Currency in AUD
0.370
-0.030(-7.50%)
Closed·
IMU is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.3700.400
52 wk Range
0.0161.785
Key Statistics
Bid/Ask
0.375 / 0.35
Prev. Close
0.37
Open
0.4
Day's Range
0.37-0.4
52 wk Range
0.016-1.785
Volume
2.32M
Average Volume (3m)
2.98M
1-Year Change
-77.79%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
IMU Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Imugene Ltd News & Analysis

Show more

Imugene Ltd Company Profile

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.

Compare IMU to Peers and Sector

Metrics to compare
IMU
Peers
Sector
Relationship
P/E Ratio
−1.6x−4.3x−0.7x
PEG Ratio
−0.03−0.090.00
Price/Book
2.4x3.9x2.6x
Price / LTM Sales
24.9x10.1x3.4x
Upside (Analyst Target)
-180.0%39.1%
Fair Value Upside
Unlock4.6%5.4%Unlock

Earnings

Latest Release
Aug 25, 2025
EPS / Forecast
-0.09 / -1.00
Revenue / Forecast
3.14M / --
EPS Revisions
Last 90 days

IMU Income Statement

People Also Watch

218.50
CSL
-0.81%
2.620
MSB
-6.43%
1.265
PNV
-9.96%
41.77
MIN
-1.69%

FAQ

What Stock Exchange Does Imugene Ltd Trade On?

Imugene Ltd is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Imugene Ltd?

The stock symbol for Imugene Ltd is "IMU."

What Is the Imugene Ltd Market Cap?

As of today, Imugene Ltd market cap is 109.46M.

What Is Imugene Ltd's Earnings Per Share (TTM)?

The Imugene Ltd EPS (TTM) is -0.32.

When Is the Next Imugene Ltd Earnings Date?

Imugene Ltd will release its next earnings report on 02 Dec 2025.

From a Technical Analysis Perspective, Is IMU a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Imugene Ltd Stock Split?

Imugene Ltd has split 6 times.

How Many Employees Does Imugene Ltd Have?

Imugene Ltd has 5 employees.

What is the current trading status of Imugene Ltd (IMU)?

As of 19 Oct 2025, Imugene Ltd (IMU) is trading at a price of 0.370, with a previous close of 0.37. The stock has fluctuated within a day range of 0.370 to 0.400, while its 52-week range spans from 0.016 to 1.785.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.